| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Over the last 12 months, insiders at Baxter International Inc. have bought $0 and sold $0 worth of Baxter International Inc. stock.
On average, over the past 5 years, insiders at Baxter International Inc. have bought $0 and sold $4.73M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 19,560 shares for transaction amount of $1.61M was made by Martin Sean (SVP and General Counsel) on 2020‑03‑30.
| 2024-03-01 | Sale | Mason Jeanne K | EVP, Chief HR Officer | 64,488 0.0126% | $40.61 | $2.62M | -12.72% | |
| 2023-02-21 | Sale | Kunzler Jacqueline | SVP, Chief Quality Officer | 3,813 0.0008% | $40.50 | $154,427 | -0.37% | |
| 2023-01-17 | Sale | Mason Jeanne K | SVP, Human Resources | 59,477 0.0118% | $44.70 | $2.66M | -8.37% | |
| 2022-04-05 | Sale | STROUCKEN ALBERT P L | 1,215 0.0002% | $76.63 | $93,105 | -26.36% | ||
| 2022-04-05 | Sale | HELLMAN PETER S | 2,827 0.0006% | $75.76 | $214,174 | -26.36% | ||
| 2022-04-01 | Sale | FORSYTH JOHN D | 1,005 0.0002% | $77.68 | $78,068 | -27.90% | ||
| 2022-03-01 | Sale | FORSYTH JOHN D | director | 1,005 0.0002% | $84.82 | $85,244 | -30.00% | |
| 2022-02-28 | Sale | Stevens Brian | SVP, CAO and Controller | 2,500 0.0005% | $85.50 | $213,757 | -30.68% | |
| 2022-02-14 | Sale | Mason Jeanne K | SVP, Human Resources | 54,143 0.0107% | $85.02 | $4.6M | -29.87% | |
| 2022-02-02 | Sale | Chen Thomas F | director | 1,680 0.0003% | $84.53 | $142,010 | -28.82% | |
| 2022-02-01 | Sale | FORSYTH JOHN D | director | 1,005 0.0002% | $85.59 | $86,018 | -27.60% | |
| 2021-11-01 | Sale | Martin Sean | SVP and General Counsel | 21,450 0.0043% | $79.57 | $1.71M | -6.90% | |
| 2021-08-02 | Sale | Martin Sean | SVP and General Counsel | 19,800 0.004% | $77.26 | $1.53M | +2.66% | |
| 2021-04-12 | Sale | Frye Andrew | SVP, President, APAC | 21,998 0.0044% | $84.79 | $1.87M | -3.28% | |
| 2021-04-05 | Sale | STROUCKEN ALBERT P L | director | 9,980 0.0013% | $57.91 | $577,942 | -3.92% | |
| 2021-04-05 | Sale | HELLMAN PETER S | director | 9,980 0.002% | $84.56 | $843,909 | -3.92% | |
| 2020-11-02 | Sale | Martin Sean | SVP and General Counsel | 94,002 0.0184% | $78.67 | $7.4M | +3.34% | |
| 2020-09-14 | Sale | FORSYTH JOHN D | director | 620 <0.0001% | $57.42 | $35,604 | -2.99% | |
| 2020-09-03 | Sale | Kunzler Jacqueline | SVP, Chief Quality Officer | 5,314 0.0011% | $85.87 | $456,313 | -3.31% | |
| 2020-08-03 | Sale | GAVIN JAMES R III | director | 29,798 0.0061% | $86.41 | $2.57M | -1.96% |
| Third Point LLC | director | 23008125 4.4549% | $471.44M | 0 | 5 | |
| Baxter Healthcare SA | 10 percent owner | 2603295 0.5041% | $53.34M | 1 | 0 | <0.0001% |
| KRAEMER HARRY M JANSEN JR | Chairman and | 694556 0.1345% | $14.23M | 1 | 0 | +11.69% |
| PARKINSON ROBERT L JR | Chairman of the Board & CEO | 465485 0.0901% | $9.54M | 2 | 6 | +5.39% |
| TUCKER MICHAEL J | Senior Vice President | 187305 0.0363% | $3.84M | 0 | 1 | |
| ANDERSON BRIAN P | Senior Vice President and | 155427 0.0301% | $3.18M | 0 | 1 | |
| GATLING JAMES M | Corporate Vice President | 151660 0.0294% | $3.11M | 0 | 10 | |
| Mason Jeanne K | EVP, Chief HR Officer | 142290 0.0276% | $2.92M | 0 | 9 | |
| JEHARAJAH NEVILLE J | Corporate Vice President | 127603 0.0247% | $2.61M | 1 | 0 | +8.1% |
| HURLEY JAMES R | Corporate Vice President | 120988 0.0234% | $2.48M | 0 | 1 | |
| Davis Robert M | Corporate Vice President | 120442 0.0233% | $2.47M | 0 | 3 | |
| GREISCH JOHN J | Corporate Vice President | 90419 0.0175% | $1.85M | 2 | 2 | +1.8% |
| HANTSON LUDWIG | Corporate Vice President | 83903 0.0162% | $1.72M | 0 | 3 | |
| Accogli Giuseppe | SVP, President, Americas | 66520 0.0129% | $1.36M | 0 | 5 | |
| DROHAN DAVID F | Senior Vice President | 61879 0.012% | $1.27M | 0 | 1 | |
| Eyre Brik V | SVP, President, Americas | 58993 0.0114% | $1.21M | 0 | 5 | |
| RIEDEL NORBERT G | Corporate Vice President | 52815 0.0102% | $1.08M | 0 | 7 | |
| Martin Sean | SVP and General Counsel | 42281 0.0082% | $866,337.69 | 1 | 3 | <0.0001% |
| Arduini Peter J | Corporate Vice President | 39855 0.0077% | $816,628.95 | 0 | 1 | |
| GAVIN JAMES R III | director | 39508 0.0076% | $809,518.92 | 0 | 8 | |
| Franzi Cristiano | SVP, President, EMEA | 39088 0.0076% | $800,913.12 | 0 | 1 | |
| DEL SALTO CARLOS | Corporate Vice President | 36289 0.007% | $743,561.61 | 0 | 4 | |
| STROUCKEN ALBERT P L | 34127 0.0066% | $699,262.23 | 6 | 9 | +7.77% | |
| HELLMAN PETER S | 28822 0.0056% | $590,562.78 | 2 | 8 | +15.47% | |
| Baughman Michael J | Corporate Vice President | 27478 0.0053% | $563,024.22 | 0 | 3 | |
| Scharf David P. | Corporate Vice President | 27369 0.0053% | $560,790.81 | 0 | 3 | |
| FORSYTH JOHN D | 27029 0.0052% | $553,824.21 | 0 | 18 | ||
| McGillivray Bruce | Corporate Vice President | 26930 0.0052% | $551,795.70 | 0 | 2 | |
| FOSLER GAIL D | director | 25627 0.005% | $525,097.23 | 0 | 2 | |
| STORM KORNELIS J. | director | 22512 0.0044% | $461,270.88 | 0 | 6 | |
| BOOMER WALTER E | director | 21005 0.0041% | $430,392.45 | 0 | 2 | |
| Utts James E | Corporate Vice President | 20408 0.004% | $418,159.92 | 0 | 2 | |
| Pleau Scott | SVP, Operations | 20076 0.0039% | $411,357.24 | 0 | 3 | |
| White Cheryl L | Corporate Vice President | 16918 0.0033% | $346,649.82 | 0 | 1 | |
| Batchelor Phillip L. | Corporate Vice President | 17083 0.0033% | $350,030.67 | 0 | 4 | |
| Devitt Blake E | director | 16541 0.0032% | $338,925.09 | 2 | 3 | +4.88% |
| Kunzler Jacqueline | SVP, Chief Quality Officer | 16725 0.0032% | $342,695.25 | 0 | 4 | |
| Stevens Brian | SVP, CAO and Controller | 14011 0.0027% | $287,085.39 | 0 | 1 | |
| Chen Thomas F | director | 12987 0.0025% | $266,103.63 | 0 | 1 | |
| HOMBACH ROBERT J. | Corporate Vice President & CFO | 12612 0.0024% | $258,419.88 | 0 | 1 | |
| ALMEIDA JOSE E | Chairman of the Board and CEO | 11691 0.0023% | $239,548.59 | 1 | 0 | +11.41% |
| Shapazian Carole J | director | 9848 0.0019% | $201,785.52 | 0 | 20 | |
| Frye Andrew | SVP, President, APAC | 9041 0.0018% | $185,250.09 | 0 | 3 | |
| MARTIN JOSEPH B | director | 8637 0.0017% | $176,972.13 | 0 | 3 | |
| Bufalino Sebastian J | Corporate Vice President | 6275 0.0012% | $128,574.75 | 0 | 2 | |
| STALLKAMP THOMAS T | director | 4737 0.0009% | $97,061.13 | 0 | 14 |
| Increased Positions | 360 | +41.67% | 84M | +16.2% |
| Decreased Positions | 370 | -42.82% | 51M | -9.89% |
| New Positions | 109 | New | 10M | New |
| Sold Out Positions | 126 | Sold Out | 14M | Sold Out |
| Total Postitions | 854 | -1.16% | 554M | +6.32% |
| Blackrock, Inc. | $1.52M | 15.14% | 77.83M | +10M | +14.91% | 2025-09-30 |
| Vanguard Group Inc | $1.22M | 12.17% | 62.53M | +335,314 | +0.54% | 2025-09-30 |
| Dodge & Cox | $1.12M | 11.17% | 57.4M | +5M | +10.12% | 2025-09-30 |
| Pzena Investment Management Llc | $1.12M | 11.17% | 57.39M | +18M | +45.89% | 2025-09-30 |
| State Street Corp | $428,946.00 | 4.28% | 22M | +60,063 | +0.27% | 2025-09-30 |
| Fmr Llc | $284,152.00 | 2.84% | 14.57M | +11M | +258.14% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $262,320.00 | 2.62% | 13.45M | -9M | -38.75% | 2025-09-30 |
| Geode Capital Management, Llc | $244,478.00 | 2.44% | 12.54M | -345,646 | -2.68% | 2025-09-30 |
| Invesco Ltd. | $169,746.00 | 1.69% | 8.7M | -198,012 | -2.22% | 2025-09-30 |
| Harris Associates L P | $165,213.00 | 1.65% | 8.47M | -875,994 | -9.37% | 2025-09-30 |